AGEN Quote, Financials, Valuation and Earnings

ANI Pharmaceuticals has a net margin of -104.99% compared to Agenus's net margin of 7.96%. Agenus's return on equity of -- beat ANI Pharmaceuticals's return on equity of -4.66%.

Agenus has a consensus price target of $11.50, signalling upside risk potential of 80.82%. On the other hand ANI Pharmaceuticals has an analysts' consensus of $81.57 which suggests that it could grow by 22.48%. Given that Agenus has higher upside potential than ANI Pharmaceuticals, analysts believe Agenus is more attractive than ANI Pharmaceuticals.

Agenus has a beta of 1.511, which suggesting that the stock is 51.137% more volatile than S&P 500. In comparison ANI Pharmaceuticals has a beta of 0.568, suggesting its less volatile than the S&P 500 by 43.195%.

Agenus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus pays -- of its earnings as a dividend. ANI Pharmaceuticals pays out -8.77% of its earnings as a dividend.

Agenus quarterly revenues are $24.1M, which are smaller than ANI Pharmaceuticals quarterly revenues of $197.1M. Agenus's net income of -$25.3M is lower than ANI Pharmaceuticals's net income of $15.7M. Notably, Agenus's price-to-earnings ratio is -- while ANI Pharmaceuticals's PE ratio is 55.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus is 1.07x versus 1.93x for ANI Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Armata Pharmaceuticals has a net margin of -104.99% compared to Agenus's net margin of --. Agenus's return on equity of -- beat Armata Pharmaceuticals's return on equity of --.

Agenus has a consensus price target of $11.50, signalling upside risk potential of 80.82%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $9.00 which suggests that it could grow by 281.36%. Given that Armata Pharmaceuticals has higher upside potential than Agenus, analysts believe Armata Pharmaceuticals is more attractive than Agenus.

Agenus has a beta of 1.511, which suggesting that the stock is 51.137% more volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.224%.

Agenus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Agenus quarterly revenues are $24.1M, which are larger than Armata Pharmaceuticals quarterly revenues of --. Agenus's net income of -$25.3M is lower than Armata Pharmaceuticals's net income of -$6.5M. Notably, Agenus's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus is 1.07x versus 1,000.03x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -104.99% compared to Agenus's net margin of --. Agenus's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Agenus has a consensus price target of $11.50, signalling upside risk potential of 80.82%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 245.76%. Given that Perspective Therapeutics has higher upside potential than Agenus, analysts believe Perspective Therapeutics is more attractive than Agenus.

Agenus has a beta of 1.511, which suggesting that the stock is 51.137% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.701%.

Agenus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Agenus quarterly revenues are $24.1M, which are larger than Perspective Therapeutics quarterly revenues of --. Agenus's net income of -$25.3M is lower than Perspective Therapeutics's net income of -$18.2M. Notably, Agenus's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus is 1.07x versus 28.76x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -104.99% compared to Agenus's net margin of -35.79%. Agenus's return on equity of -- beat Protalix BioTherapeutics's return on equity of 10.9%.

Agenus has a consensus price target of $11.50, signalling upside risk potential of 80.82%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 879.02%. Given that Protalix BioTherapeutics has higher upside potential than Agenus, analysts believe Protalix BioTherapeutics is more attractive than Agenus.

Agenus has a beta of 1.511, which suggesting that the stock is 51.137% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.227, suggesting its less volatile than the S&P 500 by 122.694%.

Agenus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Agenus quarterly revenues are $24.1M, which are larger than Protalix BioTherapeutics quarterly revenues of $10.1M. Agenus's net income of -$25.3M is lower than Protalix BioTherapeutics's net income of -$3.6M. Notably, Agenus's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 35.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus is 1.07x versus 2.01x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.